Earn points on every order New products in stock Free 51-page beginner’s guide
← Back to Compound Library

MAZDUTIDE

Another GLP-1 + glucagon dual agonist, like survodutide, but generally smoother on the stomach. Curbs appetite and nudges up energy expenditure.

Research referenceCommunity compiled

Molecular profile

The molecule itself: sequence, composition, mass, target, and registry identifiers.

Molecular formula
C₂₀₇H₃₁₇N₄₅O₆₅
Average mass
4476 Da
CAS number
2259884-03-0
Registry
PubChem CID 167312357
Receptor / pathway
GLP-1 receptorGlucagon receptor
Formula, mass and identifiers from PubChem CID 167312357.
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

Mazdutide is an advanced next-generation dual GLP-1 and Glucagon receptor co-agonist engineered for aggressive obesity reduction and metabolic disease management.

What problem it targets: It targets severe obesity, non-alcoholic fatty liver disease (MASLD/MASH), metabolic syndrome, and stubbornly stalled weight loss on single-agent GLP-1s.

What It Does

• Powerful dual-action metabolic control: Engages GLP-1 receptors to curb appetite and slow digestion while simultaneously activating glucagon receptors to dramatically boost metabolic energy expenditure.

• Clears liver fat and enhances hepatic lipid burning: Glucagon receptor activation directly stimulates hepatic fatty acid oxidation, rapidly reversing fatty liver infiltration.

• Preserves higher caloric burn: Unlike typical dieting which slows resting metabolic rate, the glucagon component keeps energy expenditure elevated even as body weight falls.

• Realistic expectations: Injected once weekly. Clinical trials demonstrate superior weight loss and hepatic fat reduction compared to standard single-mechanism GLP-1 drugs.

Reconstitution

Vial sizeBAC water / SolventConcentration
10 mg+ 2 mL5 mg/mL

Protocol

Phase (4 wks each)FrequencyDoseUnits (5 mg/mL)Notes
Weeks 1–4Once weekly1.5 mg30uStart here; smoother GI profile than survodutide.
Weeks 5–8Once weekly3 mg60u
Weeks 9–12Once weekly4.5 mg90u
Week 13+Once weekly6 mg120uMaintenance. Many cap at 4–6 mg, especially if stacked. Cycle: 4-step titration over ~12–16 weeks to 6 mg/week maintenance; each step lasts 4 weeks. Timing: same day each week, any time. Note: still raises heart rate via glucagon agonism, monitor. Women: Women lose more than men at the same dose but report more GI (start lower). In PCOS they improve cycles, lower free testosterone and raise ovulation; a real unplanned-pregnancy risk. Stop before conceiving. Men: In men, excess fat lowers testosterone; GLP-1 raises total testosterone, SHBG and gonadotropins as weight drops, and improves sperm and erectile function; and preserves fertility, unlike TRT (which suppresses sperm).

Handling & Stacking

Injection site
SubQ, abdomen/thigh. Rotate.
Storage
  • Freeze-dried: -4°F.
  • Reconstituted: 36–46°F.
  • Best used within ~3–4 weeks, kept cold (structure-based estimate, no published data); that is close to the 28- day sterility limit, so use whichever comes first.
Side effects
Nausea, diarrhea, decreased appetite, mild heart-rate increase. Generally better tolerated than survodutide.
What to expect
  • Appetite suppression plus a metabolic-rate effect; steady weight loss over months.
  • Investigational outside its approval region.
  • Supply math 10mg → 6 vials (16-wk titration to 6 mg/wk)
Pairs well with
Lipo-C / L-Carnitine (metabolic support). Standalone incretin, do not combine with other GLP-1s
Avoid
Personal/family history of medullary thyroid carcinoma or MEN2. Prior pancreatitis. Pregnancy. Other incretin stacks

Safety & Patient Education

Contraindications
Personal/family history of medullary thyroid carcinoma or MEN2 (GLP-1 class warning) Prior pancreatitis Pregnancy and lactation Severe gastroparesis
Warnings
Thyroid C-cell tumor signal in rodents (GLP-1 class) Gallbladder disease with rapid weight loss Heart-rate increase from glucagon agonism Investigational outside its region of approval
Drug interactions
Insulin / sulfonylureas: hypoglycemia risk, adjust and monitor Delayed gastric emptying alters oral drug absorption Other GLP-1 agents: do not combine
Labs
  • Fasting glucose / HbA1c (baseline + periodic) Liver enzymes; lipase if pancreatitis suspected Resting heart rate / blood pressure Renal function with significant GI losses Out of range?
  • Rising glucose/HbA1c = blood sugar creeping toward diabetes (recheck, tighten diet); a falling eGFR = kidney strain, usually dehydration (hydrate, hold the dose).
Stop criteria
Severe persistent abdominal pain (pancreatitis) Persistent vomiting / dehydration Sustained tachycardia Pregnancy
Patient education
Smoother than survodutide but still titrate stepwise Hydrate and keep protein intake up Don’t combine with other GLP-1 / incretin drugs Stop and seek care for severe abdominal pain or persistent vomiting
References
researchdosing · peptidedosages · PubMed · clinicaltrials.gov · GLP-1 sex differences · Jensterle 2020